tamoxifen

Overview

Tamoxifen is a selective estrogen receptor modulator (SERM) and one of the most widely used endocrine therapies in oncology, particularly for the treatment of hormone receptor-positive (HR+) breast cancer. It acts by competitively binding to estrogen receptors (ERs), thereby blocking estrogen-driven transcription and inhibiting the proliferation of ER-positive tumor cells. Approved for both early-stage and metastatic breast cancer, tamoxifen is prescribed over extended durations of 5–10 years, often alongside or in sequence with aromatase inhibitors such as letrozole, anastrozole, and exemestane, collectively constituting the standard hormone therapy (HT) armamentarium. Beyond oncology, tamoxifen has been investigated in non-malignant conditions, including Duchenne muscular dystrophy (DMD), where its pleiotropic cellular effects may confer therapeutic benefit independent of its antiestrogenic activity.

The drug's mechanism extends beyond direct ER antagonism: tamoxifen modulates downstream signaling cascades including the PI3K/Akt signaling pathway, NF-κB signaling, and Rac1/P-Rex1 GTPase activity, which collectively regulate cell survival, proliferation, and metastatic potential. These multi-pathway interactions underlie both its therapeutic efficacy and the complexity of resistance mechanisms that limit its long-term effectiveness in a significant subset of patients.

Focus of Latest Publications

Recent literature reflects sustained and diversified investigation of tamoxifen across breast cancer biology, resistance mechanisms, combination strategies, and emerging non-oncological indications.

Resistance Mechanisms and Molecular Reprogramming

A central theme across recent publications is the phenomenon of tamoxifen-induced chemoresistance. One study published in Life Sciences (PMID: 41819223) examined triple-positive breast cancer and demonstrated that tamoxifen-induced chemoresistance promotes cancer cell survival, progression, and metastasis, with actin-regulated cellular plasticity identified as a key determinant of the bidirectional switch between resistance and resensitization states. This finding implicates cytoskeletal dynamics as a mediator of phenotypic adaptability under endocrine therapy pressure.

Complementarily, a study in Molecular Biology Reports (PMID: 42126751) investigated the role of the miR-548as-5p/NF-κB1 axis in modulating tamoxifen sensitivity. The research demonstrated that miR-548as-5p promotes breast cancer cell apoptosis and improves tamoxifen resistance by downregulating NF-κB1, positioning this microRNA-mediated regulatory circuit as a potential therapeutic target to restore sensitivity in resistant tumors.

A study published in Nature Communications (PMID: 42115169) extended the resistance narrative by showing that endocrine therapy reprograms breast cancer cells to facilitate metastatic escape via upregulation of P-Rex1/Rac1 signaling. Critically, the study demonstrated reduced tumor burden when a targeted intervention was combined with tamoxifen in a drug-refractory patient-derived xenograft model, providing preclinical evidence for co-targeting strategies in treatment-refractory disease.

Combination Strategies and Clinical Trials

A clinical investigation published in Clinical Cancer Research (PMID: 41632450) evaluated taselisib, a selective PIK3CA inhibitor, in combination with tamoxifen in patients with metastatic HR+/HER2− breast cancer. The study assessed both safety and efficacy endpoints, as well as circulating tumor DNA dynamics, reflecting the growing integration of liquid biopsy tools in combination therapy trials. This work aligns with the broader rationale of co-inhibiting the PI3K/AKT axis to overcome or delay endocrine resistance, given the frequent PIK3CA mutations in HR+ breast cancer.

Benchmarking in Drug Discovery

In the medicinal chemistry domain, tamoxifen served as a reference standard in a study (PMID: 41932111) published in Biochemical and Biophysical Research Communications evaluating novel naphthoquinone-triazole derivatives as potential anti-breast cancer agents. Among the tested compounds, a methyl derivative (compound 2) demonstrated comparable antiproliferative potency to tamoxifen (IC₅₀ = 17.51 vs. 18.11 µM) but exhibited a markedly higher selectivity index (SI = 4.60 vs. 1.56), suggesting improved discrimination between cancerous and normal cells relative to tamoxifen.

Patient-Centered Research and Adherence

A study in JMIR Cancer (PMID: 42190242) adopted a user-centered design approach to develop a symptom diary intervention for breast cancer survivors concerned about medication brand switching. Tamoxifen was listed among the hormone therapies — alongside letrozole, anastrozole, and exemestane — prescribed for 5–10 years, underscoring the long-term adherence challenges and patient experience considerations that are increasingly recognized as critical dimensions of endocrine therapy outcomes.

Emerging Non-Oncological Applications

Tamoxifen's investigational use has extended to Duchenne muscular dystrophy. Results from Neuromuscular Disorders (PMID: 41691937) reported the safety and efficacy of tamoxifen in boys with DMD as part of the open-label extension of the TAMDMD trial — a double-blind, randomized, placebo-controlled, multicenter phase 3 study followed by a 48-week open-label extension. This application leverages tamoxifen's non-estrogenic properties, including effects on muscle membrane stability and fibrosis, in a pediatric rare disease context.

Key Publications

• Jun Aromatase inhibitory, anti-proliferative, and apoptosis-inducing effects of naphthoquinone-triazole derivatives for potential anti-breast cancer agents: In vitro and molecular docking studies. (Biochemical and biophysical research communications, 2026, PMID 41932111): "Notably, methyl derivative 2 outperformed the other derivatives with its comparable potency (IC50 = 17.51, SI = 4.60) and higher selectivity index than the standard drug, tamoxifen (IC50 = 18.11, SI = 1.56)."
• May Planning and Developing a Symptom Diary Intervention for Breast Cancer Survivors With Concerns About Medication Brands (ENABLE Study): User-Centered Design Approach. (JMIR cancer, 2026, PMID 42190242): "...patients are prescribed hormone therapy (HT) drugs (tamoxifen, letrozole, anastrozole, and exemestane) for 5-10 years."
• May PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026, PMID 41632450): "To determine the safety and efficacy of taselisib, a selective PI3K inhibitor, in combination with tamoxifen."
• May Actin-regulated plasticity as a key determinant of the bidirectional switch between chemoresistance and resensitization in triple-positive breast cancer. (Life sciences, 2026, PMID 41819223): "Tamoxifen-induced chemoresistance promotes cancer cell survival, progression, and metastasis."
• May miR-548as-5p promotes breast cancer cell apoptosis and improves tamoxifen resistance by downregulating NF-κB1. (Molecular biology reports, 2026, PMID 42126751): "Tamoxifen (TAM) resistance limits favorable outcomes in patients with breast cancer."
• May Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling. (Nature communications, 2026, PMID 42115169): "...and reduces tumour burden when combined with tamoxifen in a drug-refractory patient derived xenograft model."
• Apr Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial. (Neuromuscular disorders : NMD, 2026, PMID 41691937): "Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy was assessed in the double-blind, randomised, placebo-controlled, multicenter phase 3 trial (TAMDMD), which was followed by an 48 weeks open label extension study."